Abbreviated New Drug Application Process:
A Gift for The Industry and The Patients
Hindustan Abdul Ahad*, Haranath Chinthaginjala, Gangireddy Jayasimha Reddy,
Pasupuleti Dheeraj Krishna, Syed Rahamathulla, Jyothi Vinay Krishna
Department of Industrial Pharmacy, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) - Autonomous, Ananthapuramu – 515721, AP, India.
*Corresponding Author E-mail: abdulhindustan@gmail.com
ABSTRACT:
The United States Food and Drug Administration (USFDA) is one of the main regulated agencies wherein the submission and approval of the new drugs is done. This review is based on the process of submission to the ANDA as per FDA norms as described in paragraph IV submission in Federal Food, Drug, and Cosmetic Act (FD and C Act). No drug would exist in the market until it gets accepted by regulatory authorities. The ANDA submission is for those firms seeking to copy branded drugs before running out of patents to get profit on them. A generic applicant must provide in its application a "certification" that a patent submitted to FDA by the brand-name drug's sponsor and scheduled in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book). A Generic Product must meet the standards recognized by FDA in Reference listed drugs (RLD). This study concludes the process of ANDA submission to FDA and acts correlated to the submission in paragraph IV, the details of ANDA filling in the eCTD format and overview of the review process the checklist to the applicant.
KEYWORDS: Generic drug, submission, approval, certification, orange book.
INTRODUCTION:
Abbreviated new drug application (ANDA) comprises information that is succumbing to the Food and Drug Administration (FDA) for the analysis and potential approval of generic drug products1. As soon as accepted, an aspirant may produce and the marketplace the generic drug produces to deliver a harmless, operative, lesser price substitute to the brand-name drug its orientations.
The generic drug product is unique that is analogous to a modernizer drug produce in amount form, power, route of administration, superiority, performance appearances, and proposed use. All approved produces, both modernizer and generic, are recorded in FDA's Approved Drug Produces through Therapeutic Equivalence Evaluations (Orange Book)2.
Generic drug submissions are designated "abbreviated" since they are usually not mandatory to comprise preclinical (animal) and clinical (human) information to create protection and efficacy. Instead, generic candidates must thoroughly express that their invention performs in a similar method as the modernizer drug. One way candidates express that a generic product performs in a similar method by the modernizer drug is to the extent the period it incomes the generic drug towards degree the blood in fit volunteers. This demo of “bioequivalence” provides the absorption, or bioavailability, of the generic drug, which can formerly be narrated to that of the modernizer drug. To be approved by FDA, the generic variety must bring the same amount of active constituents into a patient's blood in a similar aggregate of time as the modernizer drug3.
The "Drug Price Competition and Patent Term Restoration Act of 1984," also known as the Hatch-Waxman Amendments, recognized bioequivalence as the source for approving generic reproductions of medicine products. These Modifications authorization FDA to accept submissions to marketplace generic varieties of brand-name medications deprived of repeating expensive and duplicative clinical trials to create protection and effectiveness. Under the Hatch-Waxman Amendments4, brand-name companies gained patent term allowance to account for the time the patented product is in appraisal by the FDA and also gain definite stages of marketing snootiness. FDA’s assistance booklets do not create officially enforceable accountabilities. Instead, guidance designates the Agency’s present thoughts on an issue and would be observed solitary as commendations, except specific supervisory or constitutional necessities are quoted. The usage of the word must in Agency supervision means that somewhat is suggested, but not mandatory. In accumulation to the ANDA approval lane, generic drug firms added the ability to test patents in court previous to selling as well as 180-day generic drug distinctiveness5. As a moment ago, drug companies could release new products with faraway less testing than is mandatory today the real assessment of a drug’s protection and effectiveness derived subsequently it left to the marketplace. If excessively numerous patients had horrendous reactions, the medication might be dragged off the shelves. The threat of this line became tragically clear when the sedative thalidomide caused thousands of upsetting natal imperfections in Europe, Canada, Latin America, Africa, and Asia. In 1970 FDA recognized the ANDA as an appliance for the assessment and authorization of the generic versions6. The ANDA approval process for the generic drugs is illustrated in figure 1.
Fig.1. ANDA drug approval process
Before 1978, generic produce candidates were mandatory to succumb complete Protection and effectiveness over clinical trials Post 1978, Candidates were mandatory to succumb distributed reports of such trials documenting protection and effectiveness. Neither of these methodologies was considered acceptable and so initiated Hatch Waxman Act in 19847.
FDA seeks frequently progress to its pre-ANDA interactions with applicants. To facilitate these communications and keep stakeholders as familiar as possible, the agency frequently circulates information on suitability petitions and Paragraph IV patent certifications[8].In the review process, FDA will send the application of the applicant to the Office of Generic Drugs (OGD)/Centre for Drug Evaluation and Research (CDER) review group for approval. If the succumbed application is not comprehensive or any shortages are acknowledged, then “refuse to file letter" is delivered by OGD/CDER to the candidate. In case the application has initiate entire without any deficiencies then it's accepted and the request is then sent to the internal review group for the documentation of Bio-Equivalence, Chemistry/Microbiology, Plant inspection and Labelling review issues.
If any incomplete fallouts are found in the application, the Bio-Equivalence deficiency letter and pending satisfactory results are delivered consequently to the candidate. Once the ANDA obedience is whole and satisfactory with no further inquiries, the applicant finally gets an FDA approval letter. GDUFA (Generic Drug User Fee Amendments) was engaged in law to speed the distribution of harmless and operative generic drugs to the community and decrease expenses to the industry. As a fragment of the assurances under the first iteration of GDUFA, FDA met certain requirements, including performance review goals for the assessment of new ANDAs. To meet these and any upcoming presentation objectives as provided for in following reauthorizations of GDUFA, FDA is delivering this guidance to assist ANDA candidates in improving the superiority of their proposals, to upsurge, the quantity of original ANDA acknowledged for receipt upon the initial proposal, and to decrease the number of ANDA review cycles9.
FDA is enthusiastic too as long as comprehensive assistance in the initial steps of the application process so that an ANDA will comprise all data necessary for FDA to whole its review in one review cycle. The CTD arrangement was recognized by the International Council for Harmonisation (ICH) of Practical Necessities for Pharmaceuticals for Human Use (ICH) in a struggle to reorganize the proposal necessities for Japan, the European Union (EU), and the United States (US)10. The CTD collects superiority, protection, and effectiveness evidence into a collective arrangement that has remained implemented by International Council for Harmonisation (ICH) regulatory authorities. The electronic Common technical document (eCTD) is the regular arrangement for electronic supervisory proposals for ANDAs. As of May-5, 2017, ANDAs and tenders to ANDAs (which includes improvements, complements, and accounts) necessity succumbed to FDA automatically in eCTD format.11, 12 FDA has delivered numerous supervision forms precise to the CTD and eCTD proposals.13 The evidence confined in this supervision attention to the procedural characteristics of filing a CTD presentation and would be studied thoroughly before succumbing to an ANDA11. This management, however, precisely reports the content of the CTD aimed at an ANDA. The modules in the ANDA approval process as described in figure 2.
The sections that survey in this assistance provide other aspects about the data that should be succumbed in the segments, units, and sections12,13.
Fig.2. The modules in ANDA approval
Essential Proof for Generics:
· Comprise the similar active constituents as the modernizer drug (quiet constituents may vary)
· Be equal in power, quantity and route of management.
· Should have same used/suggestions
· Must be bioequivalent.
· Must have similar group requirements for uniqueness, protection and pureness.
· Must monitor strict ethics of FDA’s GMPs.
Recent accompaniments to the Hatch-Waxman Act Beneath the “Medicare Prescription Drug and Modernization Act”, 2003.
· Non-extension of the 30-months.
· The time limit for the enlightening patent owner.
· Facility for allowing declaratory judgment.
· Advantage of exclusivity for numerous ANDAs filed on same day permitted.
ANDA certification clauses:
ANDA has four categories of submissions. ANDA applicants must certify to each patent for the Reference Listed Drug14.
· Paragraph I: Patent not submitted
· Paragraph II: Patent has expired
· Paragraph III: Date patent will expire
· Paragraph IV: A patent is unacceptable or will not be invaded
Resources for ANDA Submissions:
The following resources provide ANDA applicants with the legislative and governing requirements of an ANDA application, assistance from CDER to assistance one meet those necessities, and interior ANDA reviews principles, policies, and procedures. Outline tables, application forms, and other ANDA submission assets are available in ANDA Forms and Submission Requirements15.
Assistance Documents for ANDAs:
Assistance documents signify the Agency's present thoughtful on a particular topic. These documents provide strategies for the content, evaluation, and eventual approval of proposals and also to the plan, manufacture, built-up, and analysis of structured products for FDA review staff, applicants, and ANDA holders16.
· Generic Drugs guidance (Search "Generics" under topics)
· Biopharmaceutics Guidance (Search "Biopharmaceutics" under topics)
· Product-Specific Guidance for Generic Drug Development
Laws, Regulations, Policies, and Procedures:
The Federal Food, Drug, and Cosmetic Act is the elementary nourishment and medicine rule of the United States. The rule is intended to pledge clients that nutrition is pure and healthy, nontoxic to eat, and created in hygienic circumstance; that drugs and strategies are harmless and operative for their planned uses; that cosmetics are harmless and prepared from suitable ingredients; and that all labeling and packaging is honest, enlightening, and not misleading17.
Code of Federal Regulations:
The final regulations published in the Federal Register are together in the Code of Federal Regulations (CFR). Section 21 of the CFR comprises mainly of the regulations relating to nourishment and medications. The regulations file most movements of all drug candidates that are obligatory under Federal law. The following regulations directly put on to the ANDA process18:
· 21CFR Part 314: Submissions for FDA Authorization to Marketplace a Novel Drug
· 21CFR Part 320: Bioavailability and Bioequivalence Necessities Guide of Policies and Processes
CDER's Manual of Policies and Procedures:
CDER's Manual of Policies and Procedures (MAPPs) document inner performs and processes followed by the CDER team to help systematize the drug evaluation procedure and further actions, both inner and outer. Chapter 5200 covers generic drug processes and activities19.
Additional Resources:
Reference Listed Drug (RLD) Access Inquiries:
A list classifying all products about which FDA has acknowledged an investigation from a prospective generic applicant indicating that they cannot purchase the samples of the RLD necessary to support their application because of limitations on the distribution of the drug.
Investigational New Drug Application (IND):
Resources to support drug sponsors with submitting applications for approval to start new drug research on human subjects.
New Drug Application (NDA):
Resources to support drug applicants with submitting applications for authorization to marketplace a novel drug.
Pharmaceutical Quality Resources:
Resources to help meet compliance with the authorization procedure for new drug applications; comprises an evaluation of the producer's compliance with Present Good Manufacturing Practice.
Clinical Trials and Human Subject Protection:
Regulations and guidelines for scientists who design and run experiments (clinical trials) to test the protection and efficacy of new drugs on human subjects.
Surveillance: Post Drug-Approval Activities:
FDA’s post-drug-approval activities monitor the ongoing safety of marketed drugs by reconsidering drug hazards based on new data knowledgeable after the drug is marketed, and endorsing methods of demanding to most suitably manage that risk.
Small Business and Industry Assistance Program (SBIA):
CDER’s SBIA platform proposals a selection of program learning resources. The SBIA Learn net page has numerous supportive courses and soundtracks in the “Generic Drugs” section.
ANDA Filing Requirement:
ANDA Forms in directive to submit a complete ANDA, candidates must review the succeeding forms and organize all that is essential for the particular submission20.
· Filing Evaluation of ANDAs MAPP together with filing checklist
· Form FDA-356h: Right to Market a Novel Medicine, Biologic, or Antibiotic Medicine for Human Use
· Guidelines for using Form FDA-356h Form FDA-3794: GDUFA Cover Sheet
· Directives for generating a GDUFA Cover Sheet
· Form FDA-3674: Certification of Obedience
· Guidelines for the conclusion of Form FDA-3674
· Generic Medicine User Fee Payment Information
· Drug Master Files (DMFs)
Demanding a Pre-Assigned ANDA Number:
Candidates can appeal a pre-assigned ANDA number SOLITARY when succumbing to a new ANDA. If one renovating an established ANDA to eCTD, one must custom the distinctive ANDA application number. For further guidance, please sight demanding a Pre-Assigned ANDA Number21.
ANDA filing checklist:
The checklist in FDA mentioned http://fdaguidance.net /ANDA-filing-checklist/, which is most valuable for the candidate to submission of technical parts with no-fault. The ANDA Checklist is good at recitation what must be delivered, but there’s no room for detail on what has to be in each of the documents. This supervision does a much better job of describing just what makes a generic drug filing “good sufficient”. Lastly, one can argue such a denial via the contact in the refuse-to-receive letter and then intensify it via teleconference or using CDER's dispute resolution guidance22.
CONCLUSION:
The price of patented drug formulation in the market is cost-oriented for the poor. Once the patent period lapsed pharmaceutical firms plan for Abbreviated New Drug Application for seeking USFDA for manufacturing and sales of generic drug in the market. FDA’s orange book holds the details of approved drug products with therapeutic equivalence evaluations. Once the generic drug meets its specifications as the reference standards recognized by FDA then the generic drugs are also enlisted in the Orange Book. The generic drugs are available in the market at a lesser price compared to their patented drug formulations that will be benefited to small scale pharmaceutical companies and poor patients.
ACKNOWLEDGEMENT:
The authors are thankful to the college management for providing the facilities and encouragement for doing this work.
CONFLICT OF INTEREST:
The authors declare no conflict of interest.
REFERENCES:
1. Basak AK, Raw AS, Al Hakim AH, Furness S, Samaan NI, Gill DS, Patel HB, Powers RF, Yu L: Pharmaceutical impurities: regulatory perspective for abbreviated new drug applications. Advanced drug Delivery Reviews 2007, 59(1): 64-72.
2. Holovac MA: A balancing act in the United States Drug Industry: pioneer and generic drugs, the Orange Book, marketing protection and the US consumer. World Patent Information 2004, 26(2): 123-129.
3. Rafiee Z, Nejatian M, Daeihamed M, Jafari SM: Application of curcumin-loaded nanocarriers for food, drug and cosmetic purposes. Trends in Food Science and Technology 2019, 88: 445-458.
4. Weiswasser ES, Danzis SD: The Hatch-Waxman act: History, structure, and legacy. Antitrust LJ 2003, 71: 585.
5. Hu M, Babiskin A, Wittayanukorn S, Schick A, Rosenberg M, Gong X, Kim MJ, Zhang L, Lionberger R, Zhao L: Predictive analysis of first abbreviated new drug application submission for new chemical entities based on machine learning methodology. Clinical Pharmacology and Therapeutics. 2019, 106(1): 174-181.
6. Wittayanukorn S, Rosenberg M, Schick A, Hu M, Wang Z, Babiskin A, Lionberger R, Zhao L: Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions. Therapeutic Innovation and Regulatory Science. 2020, 54: 1372-1381.
7. Avery M: Continuing Abuse of the Hatch-Waxman Act by Pharmaceutical Patent Holders and the Failure of the 2003 Amendments. Hastings LJ. 2008, 60: 171.
8. Wittayanukorn S, Rosenberg M, Schick A, Hu M, Wang Z, Babiskin A, Zhao L: What factors may impact the likelihood of first abbreviated new drug application (ANDA) submission for a reference product? Value in Health. 2018, 21: S116.
9. Liu Q, Davit BM, Cherstniakova SA, Dandamudi S, Walters JF, Lee CH, Raines KW, Ren K, Williamson LN, Conner DP: Common deficiencies with bioequivalence submissions in abbreviated new drug applications assessed by FDA. The AAPS Journal. 2012, 14(1): 19-22.
10. Jordan D: An overview of the Common Technical Document (CTD) regulatory dossier. Medical Writing. 2014, 23(2): 101-105.
11. Garg V, Chopra S, Singh S, Gulati M, Kumar B, Mittal N: A comparative study of common technical document in different regulated market. Journal of Pharmacy Research. 2017, 11(8): 1015-1024.
12. Welage LS, Kirking DM, Ascione FJ, Gaither CA: Understanding the scientific issues embedded in the generic drug approval process. Journal of the American Pharmaceutical Association. (1996) 2001, 41(6): 856-867.
13. Reiffen D, Ward MR: Generic drug industry dynamics. Review of Economics and Statistics. 2005, 87(1): 37-49.
14. Pak T: Abbreviated New Drug Application. Threshold 2017, 614: 615.
15. Williamson LN, Conner DP, Stier EM, Davit BM: Common bioanalytical deficiencies with bioequivalence submissions in Abbreviated New Drug Applications. Bioanalysis 2014, 6(4): 441-445.
16. Martin R, Bahmani K: Generic drugs, a need to the public: USA and India–Government plans to reduce the price of abbreviated new drug application and list of generic drugs approved in year 2018. Journal of Generic Medicines. 2019, 15(3): 115-132.
17. Anis AH, Guh DP, Woolcott J: Lowering generic drug prices: less regulation equals more competition. Medical Care. 2003, 41(1): 135-141.
18. Brynes SD: Demystifying 21 CFR Part 556—Tolerances for residues of new animal drugs in food. Regulatory Toxicology and Pharmacology. 2005, 42(3): 324-327.
19. Jarow JP, Lemery S, Bugin K, Khozin S, Moscicki R: Expanded access of investigational drugs: the experience of the center of drug evaluation and research over a 10-year period. Therapeutic innovation and regulatory science 2016, 50(6): 705-709.
20. Bharath B, Balamuralidhara V, Venkatesh M, Gowrav M: Requirements of biopharmaceutics and clinical research for abbreviated new drug application submission-USA. Drug Invention Today. 2020, 14(7).
21. Lance PT, Greenaway RV, Edwards B: An Assessment of Concerns Regarding New Regulatory Guidance for Combination Products: A Review of the Submissions Made to the FDA Regarding Their Proposed Draft New Guidance on Human Factors Studies for a Combination Product in an Abbreviated New Drug Application. Therapeutic Innovation and Regulatory Science 2019, 53(2): 254-263.
22. Rajkumar G: Inside Story for Review of an Abbreviated New drug Application. International Journal of Drug Regulatory Affairs 2014, 2(1): 29-31.
Received on 14.06.2021 Modified on 26.06.2021
Accepted on 10.07.2021 ©AJRC All right reserved
Asian J. Research Chem. 2021; 14(5):331-335.
DOI: 10.52711/0974-4150.2021.00056